Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 5/20 | 0.63 |
| ▸ | MAOB | P27338 | 3/20 | 0.63 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.63 |
| ▸ | SDHA | P31040 | 2/20 | 0.63 |
| ▸ | LMNA | P02545 | 1/20 | 0.63 |
| ▸ | CALML3 | P27482 | 1/20 | 0.63 |
| ▸ | F10 | P00742 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4634029 | 1.00 | MAOA (0.63) | MAOAMAOBPTGS1SDHALMNA | |
| SCHEMBL10033719 | 0.94 | MAOA (0.58) | MAOAMAOBPTGS1SDHALMNA | |
| SCHEMBL10033720 | 0.92 | MAOA (0.56) | MAOAMAOBPTGS1SDHALMNA | |
| SCHEMBL2090377 | 0.92 | MAOA (0.60) | MAOAMAOBPTGS1SDHALMNA | |
| SCHEMBL10066183 | 0.90 | MAOA (0.58) | MAOAMAOBPTGS1SDHALMNA | |
| SCHEMBL10033718 | 0.90 | MAOA (0.58) | MAOAMAOBPTGS1SDHALMNA | |
| SCHEMBL10033728 | 0.90 | MAOA (0.58) | MAOAMAOBPTGS1SDHALMNA | |
| SCHEMBL10033748 | 0.88 | MAOA (0.56) | MAOAMAOBPTGS1SDHALMNA | |
| SCHEMBL4634173 | 0.88 | MAOA (0.60) | MAOAMAOBPTGS1SDHALMNA | |
| SCHEMBL4634169 | 0.88 | MAOA (0.60) | MAOAMAOBPTGS1SDHALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8513231-B2 | Use of oxazolidinone-quinoline hybrid antibiotics for the treatment of anthrax and other infections | Morphochem Aktiengesellschaft fü Kombinatorische Chemie (DE) | 2013-08-20 | — | — | US | disclosed |
| US-20120322766-A1 | USE OF OXAZOLIDINONE-QUINOLINE HYBRID ANTIBIOTICS FOR THE TREATMENT OF ANTHRAX AND OTHER INFECTIONS | MORPHOCHEM AKTIENGESELLSCHAFT FUER KOMBINATORISCHE CHEMIE (DE) | 2012-12-20 | — | — | US | disclosed |
| US-8268812-B2 | Use of oxazolidinone-quinoline hybrid antibiotics for the treatment of anthrax and other infections | Morphochem Aktiengesellschaft fül Kombinatorische Chemie (DE) | 2012-09-18 | — | — | US | disclosed |
| US-20120135961-A1 | USE OF OXAZOLIDINONE-QUINOLINE HYBRID ANTIBIOTICS FOR THE TREATMENT OF ANTHRAX AND OTHER INFECTIONS | MORPHOCHEM AKTIENGESELLSCHAFT FUR KOMBINATORISCHE CHEMIE (DE) | 2012-05-31 | — | — | US | disclosed |
| US-8124772-B2 | Intermediate products for producing oxazolidinone-quinolone hybrids | Morphochem Aktiengesellschaft für kombinatorische Chemie (DE) | 2012-02-28 | — | — | US | disclosed |
| US-8124772-B2 | Intermediate products for producing oxazolidinone-quinolone hybrids | Morphochem Aktiengesellschaft für kombinatorische Chemie (DE) | 2012-02-28 | — | — | US | disclosed |
| US-20090306389-A1 | Intermediate products for producing oxazolidinone-quinolone hybrids | MORPHOCHEM AKTIENGESELLSCHAFT FUR KOMBINATORISCHE CHEMIE (DE) | 2009-12-10 | — | — | US | disclosed |
| US-20090306389-A1 | Intermediate products for producing oxazolidinone-quinolone hybrids | MORPHOCHEM AKTIENGESELLSCHAFT FUR KOMBINATORISCHE CHEMIE (DE) | 2009-12-10 | — | — | US | disclosed |
| US-7557214-B2 | Intermediate products for producing oxazolidinone-quinolone hybrids | Morphochem Aktiengesellschaft für kombinatorische Chemie (DE) | 2009-07-07 | — | — | US | disclosed |
| US-7557214-B2 | Intermediate products for producing oxazolidinone-quinolone hybrids | Morphochem Aktiengesellschaft für kombinatorische Chemie (DE) | 2009-07-07 | — | — | US | disclosed |
| EP-1620098-B1 | USE OF OXAZOLIDINONE-QUINOLINE HYBRID ANTIBIOTICS FOR THE TREATMENT OF ANTHRAX AND OTHER INFECTIONS | MORPHOCHEM AG KOMB CHEMIE (DE) | 2008-06-11 | — | — | EP | disclosed |
| US-20070155714-A1 | Use of oxazolidinone-quinoline hybrid antibiotics for the treatment of anthrax and other infections | MORPHOCHEM AKTIENGESELLSCHAFT FUR KOMBINATORISCHE CHEMIE (DE) | 2007-07-05 | — | — | US | disclosed |
| US-20070004769-A1 | Intermediate products for producing oxazolidinone-quinolone hybrids | MORPHOCHEM AKTIEGESELLSCHAFT FUR KOMBINATORISCHE CHEMIE (DE) | 2007-01-04 | — | — | US | disclosed |
| US-20070004769-A1 | Intermediate products for producing oxazolidinone-quinolone hybrids | MORPHOCHEM AKTIEGESELLSCHAFT FUR KOMBINATORISCHE CHEMIE (DE) | 2007-01-04 | — | — | US | disclosed |
| EP-1620098-A1 | USE OF OXAZOLIDINONE-QUINOLINE HYBRID ANTIBIOTICS FOR THE TREATMENT OF ANTHRAX AND OTHER INFECTIONS | Morphochem Aktiengesellschaft Für Kombinatorische Chemie (DE) | 2006-02-01 | — | — | EP | disclosed |
| WO-2004096221-A1 | USE OF OXAZOLIDINONE-QUINOLINE HYBRID ANTIBIOTICS FOR THE TREATMENT OF ANTHRAX AND OTHER INFECTIONS | Morphochem Aktiengesellschaft für kombinatorische Chemie (DE) | 2004-11-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090306389-A1 | Intermediate products for producing oxazolidinone-quinolone hybrids | OXA1L, NQO1, NQO2 | MAOA 590/4885MAOB 391/4885PTGS1 1820/4885 |
| US-20070004769-A1 | Intermediate products for producing oxazolidinone-quinolone hybrids | OXA1L, NQO1, NQO2 | MAOA 590/4885MAOB 391/4885PTGS1 1820/4885 |
| US-20120135961-A1 | USE OF OXAZOLIDINONE-QUINOLINE HYBRID ANTIBIOTICS FOR THE TREATMENT OF ANTHRAX AND OTHER INFECTIONS | OXA1L, ANTXR2, AAAS | MAOA 1013/4885MAOB 1111/4885PTGS1 2389/4885 |
| US-20120322766-A1 | USE OF OXAZOLIDINONE-QUINOLINE HYBRID ANTIBIOTICS FOR THE TREATMENT OF ANTHRAX AND OTHER INFECTIONS | OXA1L, ANTXR2, AAAS | MAOA 1013/4885MAOB 1111/4885PTGS1 2389/4885 |
| US-20070155714-A1 | Use of oxazolidinone-quinoline hybrid antibiotics for the treatment of anthrax and other infections | OXA1L, ANTXR2, AAAS | MAOA 1013/4885MAOB 1111/4885PTGS1 2389/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.